Danaher Co. (NYSE:DHR) Receives $287.05 Consensus PT from Analysts

Danaher Co. (NYSE:DHR) has earned a consensus rating of “Moderate Buy” from the twenty ratings firms that are covering the firm, MarketBeat reports. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $287.05.

DHR has been the subject of several research analyst reports. Evercore ISI boosted their target price on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Stifel Nicolaus lifted their price objective on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a report on Wednesday, October 23rd. Royal Bank of Canada dropped their target price on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Finally, Robert W. Baird decreased their price target on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd.

Danaher Trading Up 2.2 %

NYSE:DHR opened at $234.84 on Friday. The stock has a market cap of $169.62 billion, a price-to-earnings ratio of 44.82, a price-to-earnings-growth ratio of 4.33 and a beta of 0.83. Danaher has a one year low of $222.53 and a one year high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The business’s 50-day simple moving average is $236.37 and its 200 day simple moving average is $254.34.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. Danaher’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period in the prior year, the company posted $2.02 EPS. As a group, sell-side analysts predict that Danaher will post 7.5 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.46%. Danaher’s payout ratio is 20.61%.

Institutional Investors Weigh In On Danaher

Several institutional investors have recently bought and sold shares of the stock. Benjamin Edwards Inc. lifted its stake in shares of Danaher by 1.8% in the 2nd quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock worth $538,000 after acquiring an additional 38 shares during the period. Wedge Capital Management L L P NC lifted its position in Danaher by 3.2% in the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock worth $342,000 after purchasing an additional 38 shares during the period. Certified Advisory Corp lifted its position in Danaher by 4.5% in the second quarter. Certified Advisory Corp now owns 926 shares of the conglomerate’s stock worth $231,000 after purchasing an additional 40 shares during the period. Meridian Financial Partners LLC increased its position in shares of Danaher by 4.4% during the 3rd quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock valued at $266,000 after purchasing an additional 40 shares during the period. Finally, Kovack Advisors Inc. raised its stake in shares of Danaher by 3.4% in the 3rd quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock worth $346,000 after buying an additional 41 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.